Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

131.26 -0.65 (-0.49%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark ↗

September 10, 2025

U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud...

Via Chartmill

Topics Economy

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' ↗

September 09, 2025

Novartis agreed to buy a cardiovascular-focused biotech company

Via Investor's Business Daily

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion ↗

September 09, 2025

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company.

Via Investor's Business Daily

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened ↗

September 09, 2025

Via Stocktwits

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Via Stocktwits

How Is The Market Feeling About Novartis? ↗

August 15, 2025

Via Benzinga

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver ↗

September 09, 2025

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

Via MarketBeat

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition ↗

September 09, 2025

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.

Via Benzinga

Novartis AG (NYSE:NVS) Offers a Compelling Mix of Dividend Yield, Profitability, and Financial Health ↗

September 08, 2025

Discover Novartis (NVS), a top dividend stock with a strong 3.37% yield, high profitability, and a sustainable payout for reliable income.

Via Chartmill

1 High-Yield Vanguard Dividend Fund to Buy Hand Over Fist ↗

September 05, 2025

This international dividend powerhouse quietly delivered 26.6% returns this year -- more than doubling the S&P 500 while paying triple the income.

Via The Motley Fool

Topics ETFs Stocks

P/E Ratio Insights for Novartis ↗

August 12, 2025

Via Benzinga

Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns ↗

August 11, 2025

Via Stocktwits

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗

September 05, 2025

The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.

Via The Motley Fool

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms ↗

September 04, 2025

Palantir is strengthening its role in the US industry through partnerships with Lear and Lumen and will showcase customer success stories at its AIPCon 8 event in September 2025.

Via Benzinga

Topics Artificial Intelligence

Palantir Hosts Eighth AIPCon. Stays Above 50-Day Line. Is PLTR Stock A Buy? ↗

September 04, 2025

Palantir stock bulls tout the software maker's AI strategy and strong U.S. government business amid a lofty valuation for PLTR stock.

Via Investor's Business Daily

Topics Artificial Intelligence ETFs Government

Why Did Bollinger Innovations Stock Plunge 18% Today? ↗

September 02, 2025

The company stated that it has eliminated third-party manufacturing, specifically with Roush Industries, and has instead consolidated the B4 production line from Roush Industries to the company-owned...

Via Stocktwits

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.

Via Investor's Business Daily

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗

August 29, 2025

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Via Benzinga

Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties

August 28, 2025

The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has...

Via MarketMinute

Topics Artificial Intelligence Economy Government

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗

August 28, 2025

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System ↗

August 22, 2025

UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS) – A Top Dividend Stock with Strong Yield and Financial Stability ↗

August 18, 2025

Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing.

Via Chartmill

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm ↗

August 17, 2025

These companies have successfully navigated similar obstacles before.

Via The Motley Fool

Topics Intellectual Property

2 Dividend Stocks to Buy and Hold ↗

August 15, 2025

These stocks look like they can weather almost any storm.

Via The Motley Fool

Topics Artificial Intelligence Cannabis Government

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation ↗

August 15, 2025

Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation.

Via Chartmill

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate ↗

August 13, 2025

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.

Via Benzinga

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder ↗

August 12, 2025

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

Via Benzinga

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point ↗

August 11, 2025

Truist, however, kept a ‘Buy’ rating on the shares.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.